Fintel reports that on November 4, 2025, Citizens maintained coverage of Benitec Biopharma (NasdaqCM:BNTC) with a Market ...

H.C. Wainwright raised the firm’s price target on Benitec Biopharma (BNTC) to $35 from $28 and keeps a Buy rating on the shares. The company ...

Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in ...

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has ...

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has ...

The FDA’s Fast Track designation follows the agency’s review of the interim data. BB-301 has also previously received Orphan Drug Designation from both the FDA and European Medical Association.

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence ...

HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based ...

Though many biotech investment firms have recently raised new funds to support young drugmakers, they’re cautious in deploying that cash in a turbulent economic climate. That hesitance has given ...

Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, officially becoming the world’s best-selling drug. Lilly is working to shore ...